Nature Search

Celecoxib trampled in the STAMPEDE trial

Initial results from the STAMPEDE trial of androgen deprivation therapy with and without celecoxib in patients with prostate cancer have shown that celecoxib does not confer benefit. Despite this negative finding, this multiarm, multistage trial will be informative of future clinical trial design, particularly as new agents become available for prostate cancer.

Elaine T. Lam
Thomas W. Flaig
News & Views29 May 2012
Nature Reviews Urology

Volume: 9, P: 358-360
The dawn of personalized medicine

Long awaited data from the clinical investigation of bladder cancer in both the neoadjuvant and adjuvant settings were released in 2011, setting the stage for the next generation of work in this area. The findings of a number of studies provide the first steps towards a personalized approach to this disease.

Thomas W. Flaig
Dan Theodorescu
News & Views20 Dec 2011
Nature Reviews Urology

Volume: 9, P: 65-66
Clinical characteristics and treatment of patients with small cell prostate cancer: analysis of a real-world cohort from an oncology database

Corbin J. Eule
Adam Warren
Thomas W. Flaig
Research21 Nov 2024
Prostate Cancer and Prostatic Diseases

Volume: 28, P: 444-450
Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records

Current understanding of Long COVID is limited, in part, due to lack of evidence from population-representative studies. Here, the authors analyse data from ten UK population-based studies and electronic health records, and find wide variation in the frequency of Long COVID between studies but some consistent risk factors.

Ellen J. Thompson
Dylan M. Williams
Claire J. Steves
ResearchOpen Access28 Jun 2022
Nature Communications

Volume: 13, P: 1-11
Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations

Corbin J. Eule
Thomas W. Flaig
Elaine T. Lam
Research19 Nov 2022
Prostate Cancer and Prostatic Diseases

Volume: 26, P: 188-193
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease

The SARS-CoV-2 main protease is an important target for the development of COVID-19 therapeutics. Here, the authors combine X-ray crystallography and mass spectrometry and performed a large scale fragment screening campaign, which yielded 96 liganded structures of this essential viral protein that are of interest for further drug development efforts.

Alice Douangamath
Daren Fearon
Martin A. Walsh
ResearchOpen Access07 Oct 2020
Nature Communications

Volume: 11, P: 1-11
Clinical opportunities and challenges in targeting tumour dormancy

Tumour dormancy is when cancer sleeps undetected for periods that can last up to decades. The therapeutic potential of inducing or maintaining this dormant period is clear. This Review describes the mechanisms of dormancy and uses genitourinary cancers as models to demonstrate how dormancy principles could be exploited clinically.

Jonathan A. Hensel
Thomas W. Flaig
Dan Theodorescu
Reviews27 Nov 2012
Nature Reviews Clinical Oncology

Volume: 10, P: 41-51
Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning

Zilong Bai
Mohamed Osman
Fei Wang
ResearchOpen Access22 Mar 2025
npj Digital Medicine

Volume: 8, P: 1-12
Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

A focus group of specialized urologic oncologists has reviewed guidelines and clinical evidence and discussed their experiences regarding the optimal use of BCG in the management of patients with NIMBC. Here, they provide a review of BCG therapy, clarify complex related topics and recommend best practice guidelines to improve BCG use and patient outcomes.

Ashish M. Kamat
Thomas W. Flaig
John A. Taylor III
ReviewsOpen Access24 Mar 2015
Nature Reviews Urology

Volume: 12, P: 225-235
Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes

In this Review, Meeks et al. summarize heterogeneity in bladder cancer and how it affects tumour biology and clinical care. They describe current knowledge of tumour evolution, genomic heterogeneity and different tumour subtypes, as well as morphological heterogeneity seen in variant bladder cancer histology. They also discuss the influence of heterogeneity on treatment decision making, drug development and clinical trial design.

Joshua J. Meeks
Hikmat Al-Ahmadie
Lars Dyrskjøt
Reviews31 Mar 2020
Nature Reviews Urology

Volume: 17, P: 259-270
Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib

T W Flaig
L J Costa
H Drabkin
ResearchOpen Access07 Sept 2010
British Journal of Cancer

Volume: 103, P: 796-801

Search

Filter By:

Search

Quick links